granisetron has been researched along with aprepitant in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.77) | 18.2507 |
| 2000's | 10 (18.87) | 29.6817 |
| 2010's | 34 (64.15) | 24.3611 |
| 2020's | 7 (13.21) | 2.80 |
| Authors | Studies |
|---|---|
| Carides, AD; Gertz, BJ; Gralla, RJ; Grote, TH; Grunberg, SM; Hesketh, PJ; Khojasteh, A; Kindler, H; Kris, MG; Navari, RM; Pendergrass, K; Reinhardt, RR | 1 |
| O'Sullivan, GC; Shanahan, F | 1 |
| Campos, D; Carides, AD; Carracedo, C; Erazo, A; Eriksson, LO; Gertz, BJ; Martinez-Cedillo, J; Pereira, JR; Poli, S; Reinhardt, RR; Vogel, C; Wittreich, J | 1 |
| Aapro, M; Carides, AD; Evans, JK; Hargreaves, R; Hesketh, PJ; Horgan, KJ; Naylor, RJ; Tattersall, FD; Van Belle, S | 1 |
| Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA | 1 |
| Herrstedt, J | 1 |
| Wilkes, G | 1 |
| Awata, H; Hashimoto, Y; Katayama, M; Kitagawa, J; Kodama, Y; Miyata, Y; Nakade, S; Ohno, T | 1 |
| Szántó, J; Tóth, J | 1 |
| Behlendorf, T; Jordan, K; Kinitz, I; Schmoll, HJ; Voigt, W; Wolf, HH | 1 |
| Eguchi, K; Hoshi, E; Katsumata, N; Kawahara, M; Takagi, M; Takahashi, T | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
| Endo, M; Murakami, H; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Dakhil, SR; Heckler, CE; Kuebler, JP; Mohile, SG; Morrow, GR; Roscoe, JA; Wade, JL | 1 |
| Eguchi, K; Katakami, N; Katsumata, N; Kawahara, M; Saito, H; Yoshimori, K; Yoshizawa, H | 1 |
| Fujimura, T; Fushida, S; Hirono, Y; Hirosawa, H; Kaji, M; Kimura, H; Kinami, S; Kinoshita, J; Nakano, T; Ohta, T; Oyama, K; Takai, Y; Takeda, T; Tsukada, T; Tsuneda, A; Yabushita, K; Yasui, T; Yoshimoto, K | 1 |
| Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Oishi, R; Sakurai, A; Takenaka, K; Teshima, T; Uchida, M | 1 |
| Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M | 1 |
| Hatake, K; Ito, Y; Nakayama, Y; Takahashi, S; Tanabe, M | 1 |
| Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Nagata, K; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Goto, H; Myojo, T; Osawa, H | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Asano, K; Ito, Y; Kim, S; Ogura, Y; Tasaka, A; Yamamoto, K; Yamatodani, A | 1 |
| Burhenne, J; Egerer, G; Freiberger, A; Goldschmidt, H; Gronkowski, M; Ho, AD; Hüsing, J; Mikus, G; Neben, K; Pelzl, le H; Schmitt, T; Thalheimer, M | 1 |
| Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N | 1 |
| Aoki, Y; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Kato, T; Kimura, H; Nishida, H; Shimozaki, S; Shirai, T; Takeuchi, A; Tanzawa, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Fujiwara, S; Kanemura, M; Ohmichi, M; Sasaki, H; Terai, Y; Tsunetoh, S | 1 |
| Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Hashizume, J; Higuchi, N; Kitahara, T; Kodama, Y; Matsunaga, N; Nakamura, T; Sakamoto, T; Sasaki, H; Sato, K; Yamaguchi, K | 1 |
| Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T | 1 |
| Asada, K; Enomoto, N; Fujisawa, T; Hayakawa, H; Imokawa, S; Inui, N; Karayama, M; Kuroishi, S; Masuda, M; Nakamura, Y; Suda, T; Suzuki, S; Toyoshima, M; Watanabe, H; Yamada, T; Yokomura, K | 1 |
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T | 1 |
| Chen, YX; Chen, ZD; Cheng, Y; Dang, CX; Dong, J; Han, BH; Hu, B; Li, BL; Li, JL; Liu, B; Lu, JG; Qin, SK; Shi, JH; Shu, YQ; Sun, XC; Wang, D; Wang, HB; Wang, KM; Wang, QM; Wu, Q; Yang, LQ; Zhang, HL; Zhang, QY; Zhang, ZH | 1 |
| Iida, H; Kojima, Y; Matsumoto, S; Miyazawa, K; Nagai, H; Nakamura, A | 1 |
| Akashi, K; Hosohata, K; Ikesue, H; Kato, K; Makihara, Y; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Suetsugu, K; Uchida, M | 1 |
| Goto, K; Hama, T; Hashimoto, H; Itoh, K; Kawasaki, Y; Matsui, R; Seki, N; Suzuki, K; Tsuji, D; Yamamoto, N; Yamanaka, T | 1 |
| Abe, M; Fujita, Y; Hayasaki, Y; Iihara, H; Matsuoka, R; Morishige, K; Nagasawa, Y; Sakurai, M; Shimokawa, M; Suzuki, A | 1 |
| Araz, M; Artac, M; Beypinar, I; Inci, F; Karaagac, M; Koral, L; Korkmaz, L; Uysal, M | 1 |
| Binder, G; Botteman, M; Corman, S; Nickel, K; Turini, M | 1 |
| Alweshahy, S; Elshabasy, DA; Tantawy, MA; Youssef, NF | 1 |
| Abe, M; Arai, T; Fujita, Y; Hayasaki, Y; Iihara, H; Kado, N; Mori, M; Morishige, KI; Murase, S; Nakamura, K; Sakurai, M; Shimaoka, R; Shimokawa, M; Suzuki, A; Takenaka, M; Yamamoto, S | 1 |
| Burckart, G; Garimella, N; Griebel, D; Heinrichs, MT; Kim, I; Krudys, K; Kumar, S; Mehrotra, N; Momper, JD; Mulberg, AE; Mulugeta, Y; Nelson, R; Reaman, G; Sachs, H; Sinha, V; Yao, L; Zineh, I | 1 |
| Ebrahimi, M; Mehrzad, V; Moghaddas, A | 1 |
| A El-Azab, G; A Mahrous, M; A Tawfik, H | 1 |
| Hiraki, Y; Hori, M; Kawanaka, H; Matsuo, N; Miyashita, H; Miyoshi, T; Odawara, M | 1 |
| Araki, T; Nagamine, A; Obayashi, K; Ohshima, S; Takahashi, E; Takahashi, Y; Uchiyama, C; Yamamoto, K; Yashima, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
6 review(s) available for granisetron and aprepitant
| Article | Year |
|---|---|
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Granisetron; Humans; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Ondansetron; Prodrugs; Serotonin; Serotonin Antagonists; Substance P; Vomiting | 2003 |
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Topics: Adult; Antiemetics; Aprepitant; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Granisetron; Half-Life; Humans; Male; Middle Aged; Morpholines; Ondansetron; Randomized Controlled Trials as Topic | 2003 |
[Medical treatment of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Ghrelin; Glucocorticoids; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Peptide Hormones; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2007 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Primary Prevention; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting | 2008 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
21 trial(s) available for granisetron and aprepitant
| Article | Year |
|---|---|
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
Topics: Acetals; Aged; Antiemetics; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Patient Satisfaction; Serotonin Antagonists; Vomiting | 1999 |
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiemetics; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Neoplasms; Vomiting | 2001 |
Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Biological Availability; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Morpholines; Nausea; Vomiting | 2008 |
Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Asian People; Cisplatin; Constipation; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Granisetron; Hiccup; Humans; Japan; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Placebos; Treatment Outcome | 2010 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Immunoenzyme Techniques; Japan; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Morpholines; Nausea; Small Cell Lung Carcinoma; Substance P; Vomiting; Young Adult | 2011 |
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Prochlorperazine; Quinuclidines; Serotonin Antagonists | 2012 |
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Vomiting | 2013 |
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2015 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
Topics: Aprepitant; Dexamethasone; Double-Blind Method; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Morpholines; Multiple Myeloma; Nausea; Prospective Studies; Quality of Life; Transplantation, Autologous; Vomiting | 2014 |
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-da
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Bone Neoplasms; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2015 |
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cross-Over Studies; Diet; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Granisetron; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Paclitaxel; Pemetrexed; Vomiting | 2016 |
Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cross-Over Studies; Dexamethasone; Esophageal Neoplasms; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Stomach Neoplasms; Vomiting | 2016 |
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Asian People; China; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Nausea; Treatment Outcome; Vomiting; Young Adult | 2017 |
Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Risk Factors; Vomiting | 2019 |
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Carboplatin; Dexamethasone; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Granisetron; Humans; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2019 |
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Granisetron; Humans; Middle Aged; Nausea; Olanzapine; Vomiting | 2020 |
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Egypt; Female; Granisetron; Humans; Male; Middle Aged; Nausea; Palonosetron; Quality of Life; Vomiting | 2021 |
Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Female; Granisetron; Humans; Incidence; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Retrospective Studies; Treatment Outcome; Vomiting | 2021 |
26 other study(ies) available for granisetron and aprepitant
| Article | Year |
|---|---|
Neurokinin antagonism and chemotherapy-induced emesis.
Topics: Acetals; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Female; Granisetron; Humans; Male; Morpholines; Multicenter Studies as Topic; Nausea; Neurokinin-1 Receptor Antagonists; Randomized Controlled Trials as Topic; Substance P; Vomiting | 1999 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Dexamethasone; Drug Administration Schedule; Female; Granisetron; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Safety; Treatment Outcome | 2009 |
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasm Staging; Oxonic Acid; Prospective Studies; Psychometrics; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome; Vomiting | 2013 |
Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug Therapy, Combination; Female; Granisetron; Hematologic Neoplasms; Hospitals, University; Humans; Male; Middle Aged; Morpholines; Nausea; Retrospective Studies; Treatment Outcome; Vomiting; Young Adult | 2013 |
Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Asian People; Female; Granisetron; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Retrospective Studies; Treatment Outcome; Vomiting; Young Adult | 2013 |
Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Morpholines; Nausea; Retrospective Studies; Transplantation, Homologous; Vomiting | 2013 |
[Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a sin
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Combinations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Risk; Vomiting | 2013 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |
Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Eating; Granisetron; Kaolin; Male; Medulla Oblongata; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Pica; Protein Precursors; Rats, Wistar; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; RNA, Messenger; Serotonin Antagonists; Solitary Nucleus; Substance P; Tachykinins | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Fluorouracil; Granisetron; Head and Neck Neoplasms; Humans; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Prospective Studies; Treatment Outcome; Vomiting | 2014 |
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; Morpholines; Nausea; Neoplasm Metastasis; Ondansetron | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Oxonic Acid; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Stomach Neoplasms; Surveys and Questionnaires; Tegafur; Vomiting | 2016 |
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Compounds, Heterocyclic; Catheterization, Peripheral; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Liver; Liver Neoplasms; Male; Middle Aged; Morpholines; Nausea; Oxazines; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Fluorouracil; Granisetron; Humans; Leucovorin; Male; Morpholines; Organoplatinum Compounds; Vomiting | 2016 |
Clinical Impact of Aprepitant in Patients Receiving High-Dose Chemotherapy prior to Autologous Peripheral Blood Stem Cell Transplantation: A Cost-Effectiveness Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Aprepitant; Cost-Benefit Analysis; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Morpholines; Multiple Myeloma; Nausea; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Vomiting | 2017 |
Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bendamustine Hydrochloride; Dexamethasone; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Retrospective Studies; Vomiting | 2018 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Palonosetron; Prospective Studies; Vomiting | 2019 |
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Topics: Antiemetics; Aprepitant; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Vomiting | 2020 |
Simultaneous Determination of Co-administrated Deflazacort, Aprepitant and Granisetron in Dosage Forms and Spiked Human Plasma by RP-HPLC/PAD.
Topics: Aprepitant; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Granisetron; Humans; Limit of Detection; Linear Models; Pregnenediones; Reproducibility of Results | 2019 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Granisetron; Humans; Infant; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Palonosetron; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting; Young Adult | 2020 |
Adherence to ASCO for Prophylaxis of Acute Chemotherapy- Induced Nausea and Vomiting in Iran.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Granisetron; Guideline Adherence; Humans; Induction Chemotherapy; Male; Middle Aged; Nausea; Neoplasms; Prognosis; Vomiting | 2020 |
Comparison of the Antiemetic Effect of Aprepitant/granisetron and Palonosetron Combined with Dexamethasone in Gynecological Cancer Patients Treated with Paclitaxel and Carboplatin Combination Regimen.
Topics: Anorexia; Antiemetics; Aprepitant; Carboplatin; Dexamethasone; Female; Granisetron; Humans; Nausea; Neoplasms; Paclitaxel; Palonosetron; Retrospective Studies; Vomiting | 2022 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |